Scientific advisor and co-founder
Regina Grillari is associate professor for cellular biology since 2008 and has been leading a group focused on cellular immortalization and cell line development for more than 10 years at the Department of Biotechnology, University of Natural Resources and Applied Life Sciences Vienna, Austria. She achieved her PhD in 2000 on immortalization of human cells and recombinant protein expression and was appointed to receive the Prof. Anton Kurir habilitation award in 2009. In 2012 she received the “Phoenix Award” for successful academic entrepreneurship from the Austrian Ministry of Science and Research and 2015 she achieved third place of the Houska Award of the B&C Holding. Furthermore Regina Grillari has authored and co-authored more than 50 scientific publications and book chapters, 4 patents. In addition she is co-founder and CTO of Evercyte GmbH (est. 2011), co-founder of Phoenestra GmbH (2015) and also co-founder and scientific advisor of Remute Bio GmbH (2016).
Scientific advisor and co-founder
Johannes Grillari has more than 10 years of experience as a group leader in cellular and molecular aging research. Since 2006 he is associate professor at the Department of Biotechnology, University of Natural Resources and Life Sciences Vienna, Austria. He did his PhD degree between 1996 and 1999 on senescence of endothelial cells and worked as a visiting scientist at the University of Dundee, Scotland, UK. He has authored and co-authored more than 63 scientific articles and book chapters, 6 patents, and was invited as speaker more than 70 times to international meetings. Furthermore, Johannes Grillari is co-founder and CSO of Evercyte GmbH (est. 2011), co-founder of Phoenestra GmbH (founded 2015) and co-founder and scientific advisor of Remute Bio GmbH (2016).
Since 1998 Heinz Redl is the director of the Ludwig Boltzmann Institute for Experimental and Clinical Traumatology. In his group, Dr. Redl has pioneered research in the field of tissue/bone regeneration and has lead the development of innovative approaches to bone healing.
Prof. Redl assists in TAmiRNA in the design and conduction of pre-clinical trials.
Peter Pietschmann is Deputy Head at the Department of Pathophysiology at the Medical University of Vienna since 2006 after being appointed as Associate Professor in 2002. His group is conducting research on the pathophysiology of bone fragility and the relation of bone strength to gene expression. He has published 169 papers in peer-reviewed journals in the area of Osteoporosis and was honored with several awards. Dr. Pietschmann is currently serving as President of the Austrian Society of Bone and Mineral Research, and former president of the Austrian Society of Geriatrics & Gerontology.
Peter Pietschmann supports TAmiRNA in scientific and strategic decisions in developing novel biomarkers for risk assessment in osteoporosis.
As a former professor of the Medical University of Vienna, Prof. Woloszczuk was involved in the development of numerous biochemical biomarkers and diagnostic tests for bone diseases. He co-founded the Biomedica GmbH, which specializes in the development and commercialization of diagnostic products.
Prof. Woloszczuk supports TAmiRNA in strategic decisions in respect to development and marketing of its novel biomarker tests.